Characteristics of patients (> 18 y) who underwent a myeloablative 8/8 matched URD or HLA-identical sibling transplantation between 1995 and 2004 for AML, ALL, and CML
| Characteristics . | HLA-identical siblings . | URD . | P . |
|---|---|---|---|
| Total patients, n (%) | 3158 (77) | 941 (23) | |
| Median recipient age at transplantation, y (range) | |||
| Recipient | 38.1 (18-59.9) | 38.9 (18-59.9) | .09 |
| Donor | 37 (18-60) | 35.5 (19-59.3) | < .001 |
| Male sex | 1768 (56) | 526 (56) | |
| Donor-recipient sex match | < .001 | ||
| Male→male | 1039 (33) | 369 (39) | |
| Male→female | 723 (23) | 250 (27) | |
| Female→male | 728 (23) | 157 (17) | |
| Female→female | 659 (21) | 165 (18) | |
| Unknown | 9 (< 1) | 0 | |
| Disease | .001 | ||
| AML | 1271 (40) | 340 (36) | |
| ALL | 483 (15) | 189 (20) | |
| CML | 1404 (44) | 412 (44) | |
| Disease status at transplantation* | < .001 | ||
| Early | 2203 (70) | 476 (51) | |
| Intermediate | 468 (15) | 243 (26) | |
| Advanced | 449 (14) | 222 (24) | |
| Unknown | 38 (1) | 0 | |
| Karnofsky performance score | < .001 | ||
| < 90 | 678 (21) | 238 (25) | |
| 90-100 | 2441 (77) | 651 (69) | |
| Unknown | 39 (1) | 52 (6) | |
| Donor-recipient CMV match | < .001 | ||
| D(−)/R(−) | 766 (24) | 306 (33) | |
| D(−)/R(+) | 409 (13) | 286 (30) | |
| D(+)/R(−) | 276 (9) | 137 (15) | |
| D(+)/R(+) | 1527 (48) | 188 (20) | |
| Unknown | 180 (6) | 24 (3) | |
| Graft type | < .001 | ||
| Bone marrow | 1788 (57) | 748 (79) | |
| Peripheral blood | 1370 (43) | 193 (21) | |
| Conditioning regimen | < .001 | ||
| cy + tbi ± other | 1237 (39) | 738 (78) | |
| cy + bu ± other | 1921 (61) | 203 (22) | |
| ATG during conditioning | 31 (1) | 48 (5) | |
| GVHD prophylaxis | < .001 | ||
| CSA + MTX ± other | 3007 (95) | 648 (69) | |
| FK506 + MTX ± other | 151 (5) | 293 (31) | |
| Median follow-up of survivors, mo (range) | 60.3 (1.4-136.7) | 72.2 (10.8-135.3) | < .001 |
| Year of transplantation | < .001 | ||
| 1995-1997 | 1456 (46) | 250 (27) | |
| 1998-2000 | 972 (31) | 327 (35) | |
| 2001-2004 | 730 (23) | 364 (39) | |
| Acute leukemia | |||
| AML FAB subtype | < .001 | ||
| AML M1 | 189 (15) | 50 (15) | |
| AML M2 | 342 (28) | 71 (21) | |
| AML M3 | 117 (10) | 16 (5) | |
| AML M4 | 256 (21) | 63 (19) | |
| AML M5 | 154 (13) | 26 (8) | |
| AML M6 | 29 (2) | 18 (5) | |
| AML M7 | 15 (1) | 7 (2) | |
| Other AML | 48 (4) | 23 (7) | |
| Unclassified AML | 76 (6) | 57 (17) | |
| WBC at diagnosis | < .001 | ||
| < 25 × 109/L | 994 (57) | 246 (47) | |
| 25-50 × 109/L | 191 (11) | 60 (11) | |
| 50-100 × 109/L | 206 (12) | 49 (9) | |
| > 100 × 109/L | 144 (8) | 59 (11) | |
| Missing | 219 (12) | 115 (22) | |
| Median WBC at diagnosis, ×109/L (range) | 21.1 (0.1-900) | 14.7 (0.3-870) | .001 |
| Duration of CR1 (for patients beyond CR1) | < .001 | ||
| < 6 mo | 186 (35) | 77 (27) | |
| 6-12 mo | 92 (17) | 75 (27) | |
| > 12 mo | 157 (29) | 98 (35) | |
| Missing | 104 (19) | 32 (11) | |
| Median (range), mo | 8.0 (0.1-151.1) | 9.6 (0.6-145.2) | .008 |
| Time from remission to transplantation (for patients in CR1) | < .001 | ||
| < 3 mo | 463 (45) | 71 (39) | |
| 3-6 mo | 376 (36) | 77 (42) | |
| > 6 mo | 134 (13) | 34 (19) | |
| Missing | 60 (6) | 0 | |
| Median (range), mo | 3.1 (0.06-46.8) | 3.6 (0.2-20.5) | .249 |
| Cytogenetics: AML | < .001 | ||
| Good prognosis | 140 (11) | 35 (10) | |
| Intermediate prognosis | 188 (15) | 53 (16) | |
| Poor prognosis | 158 (12) | 60 (18) | |
| No abnormalities | 469 (37) | 72 (21) | |
| Unknown | 316 (25) | 120 (35) | |
| Cytogenetics: ALL | < .001 | ||
| No abnormalities | 154 (32) | 36 (19) | |
| Hyperdiploid | 36 (7) | 18 (10) | |
| Hypodiploid, t(9;22), t(4;11), t(8;14) | 73 (15) | 56 (30) | |
| Other abnormalities | 84 (17) | 24 (13) | |
| Unknown | 136 (28) | 55 (29) | |
| Chronic leukemia | |||
| CML: Time from diagnosis to transplantation | < .001 | ||
| < 12 mo | 893 (64) | 210 (51) | |
| 12-24 mo | 325 (23) | 110 (27) | |
| > 24 mo | 186 (13) | 91 (22) | |
| Missing | 0 | 1 (< 1) | |
| Median (range), mo | 8.7 (0.7-149.9) | 11.8 (0.9-138.7) | < .001 |
| Grade II-IV acute GVHD | 1083 (34) | 485 (52) | |
| Grade III-IV acute GVHD | 495 (16) | 194 (21) | |
| Chronic GVHD | 1308 (42) | 465 (49) |
| Characteristics . | HLA-identical siblings . | URD . | P . |
|---|---|---|---|
| Total patients, n (%) | 3158 (77) | 941 (23) | |
| Median recipient age at transplantation, y (range) | |||
| Recipient | 38.1 (18-59.9) | 38.9 (18-59.9) | .09 |
| Donor | 37 (18-60) | 35.5 (19-59.3) | < .001 |
| Male sex | 1768 (56) | 526 (56) | |
| Donor-recipient sex match | < .001 | ||
| Male→male | 1039 (33) | 369 (39) | |
| Male→female | 723 (23) | 250 (27) | |
| Female→male | 728 (23) | 157 (17) | |
| Female→female | 659 (21) | 165 (18) | |
| Unknown | 9 (< 1) | 0 | |
| Disease | .001 | ||
| AML | 1271 (40) | 340 (36) | |
| ALL | 483 (15) | 189 (20) | |
| CML | 1404 (44) | 412 (44) | |
| Disease status at transplantation* | < .001 | ||
| Early | 2203 (70) | 476 (51) | |
| Intermediate | 468 (15) | 243 (26) | |
| Advanced | 449 (14) | 222 (24) | |
| Unknown | 38 (1) | 0 | |
| Karnofsky performance score | < .001 | ||
| < 90 | 678 (21) | 238 (25) | |
| 90-100 | 2441 (77) | 651 (69) | |
| Unknown | 39 (1) | 52 (6) | |
| Donor-recipient CMV match | < .001 | ||
| D(−)/R(−) | 766 (24) | 306 (33) | |
| D(−)/R(+) | 409 (13) | 286 (30) | |
| D(+)/R(−) | 276 (9) | 137 (15) | |
| D(+)/R(+) | 1527 (48) | 188 (20) | |
| Unknown | 180 (6) | 24 (3) | |
| Graft type | < .001 | ||
| Bone marrow | 1788 (57) | 748 (79) | |
| Peripheral blood | 1370 (43) | 193 (21) | |
| Conditioning regimen | < .001 | ||
| cy + tbi ± other | 1237 (39) | 738 (78) | |
| cy + bu ± other | 1921 (61) | 203 (22) | |
| ATG during conditioning | 31 (1) | 48 (5) | |
| GVHD prophylaxis | < .001 | ||
| CSA + MTX ± other | 3007 (95) | 648 (69) | |
| FK506 + MTX ± other | 151 (5) | 293 (31) | |
| Median follow-up of survivors, mo (range) | 60.3 (1.4-136.7) | 72.2 (10.8-135.3) | < .001 |
| Year of transplantation | < .001 | ||
| 1995-1997 | 1456 (46) | 250 (27) | |
| 1998-2000 | 972 (31) | 327 (35) | |
| 2001-2004 | 730 (23) | 364 (39) | |
| Acute leukemia | |||
| AML FAB subtype | < .001 | ||
| AML M1 | 189 (15) | 50 (15) | |
| AML M2 | 342 (28) | 71 (21) | |
| AML M3 | 117 (10) | 16 (5) | |
| AML M4 | 256 (21) | 63 (19) | |
| AML M5 | 154 (13) | 26 (8) | |
| AML M6 | 29 (2) | 18 (5) | |
| AML M7 | 15 (1) | 7 (2) | |
| Other AML | 48 (4) | 23 (7) | |
| Unclassified AML | 76 (6) | 57 (17) | |
| WBC at diagnosis | < .001 | ||
| < 25 × 109/L | 994 (57) | 246 (47) | |
| 25-50 × 109/L | 191 (11) | 60 (11) | |
| 50-100 × 109/L | 206 (12) | 49 (9) | |
| > 100 × 109/L | 144 (8) | 59 (11) | |
| Missing | 219 (12) | 115 (22) | |
| Median WBC at diagnosis, ×109/L (range) | 21.1 (0.1-900) | 14.7 (0.3-870) | .001 |
| Duration of CR1 (for patients beyond CR1) | < .001 | ||
| < 6 mo | 186 (35) | 77 (27) | |
| 6-12 mo | 92 (17) | 75 (27) | |
| > 12 mo | 157 (29) | 98 (35) | |
| Missing | 104 (19) | 32 (11) | |
| Median (range), mo | 8.0 (0.1-151.1) | 9.6 (0.6-145.2) | .008 |
| Time from remission to transplantation (for patients in CR1) | < .001 | ||
| < 3 mo | 463 (45) | 71 (39) | |
| 3-6 mo | 376 (36) | 77 (42) | |
| > 6 mo | 134 (13) | 34 (19) | |
| Missing | 60 (6) | 0 | |
| Median (range), mo | 3.1 (0.06-46.8) | 3.6 (0.2-20.5) | .249 |
| Cytogenetics: AML | < .001 | ||
| Good prognosis | 140 (11) | 35 (10) | |
| Intermediate prognosis | 188 (15) | 53 (16) | |
| Poor prognosis | 158 (12) | 60 (18) | |
| No abnormalities | 469 (37) | 72 (21) | |
| Unknown | 316 (25) | 120 (35) | |
| Cytogenetics: ALL | < .001 | ||
| No abnormalities | 154 (32) | 36 (19) | |
| Hyperdiploid | 36 (7) | 18 (10) | |
| Hypodiploid, t(9;22), t(4;11), t(8;14) | 73 (15) | 56 (30) | |
| Other abnormalities | 84 (17) | 24 (13) | |
| Unknown | 136 (28) | 55 (29) | |
| Chronic leukemia | |||
| CML: Time from diagnosis to transplantation | < .001 | ||
| < 12 mo | 893 (64) | 210 (51) | |
| 12-24 mo | 325 (23) | 110 (27) | |
| > 24 mo | 186 (13) | 91 (22) | |
| Missing | 0 | 1 (< 1) | |
| Median (range), mo | 8.7 (0.7-149.9) | 11.8 (0.9-138.7) | < .001 |
| Grade II-IV acute GVHD | 1083 (34) | 485 (52) | |
| Grade III-IV acute GVHD | 495 (16) | 194 (21) | |
| Chronic GVHD | 1308 (42) | 465 (49) |
Characteristics of URD or HLA-identical sibling transplantations and differences between the 2 groups regarding some prognostic factors are shown. Unless otherwise indicated, all values are no. (%).
URD indicates unrelated donor; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; cy, cyclophosphamide; tbi, total body irradiation; bu, busulpan; ATG, anti–T-cell immunoglobulin; CSA, cyclosporine; MTX, methotrexate; FK506, tacrolimus; FAB, French-American-British; WBC, white blood cell; CR1, first complete remission; and GVHD, graft-versus-host disease.
Disease status is categorized as follows: early includes AML and ALL in CR1 or CML in first chronic phase; intermediate includes AML and ALL in ≥ CR2 or CML in accelerated phase or ≥ second chronic phase; and advanced includes AML and ALL with relapse or primary induction failure or CML in blast crisis.